Allergies & Asthma

For 70 years the Asthma and Allergy Foundation of America has provided trusted information to help the asthma and allergy community improve their health and have a voice in decisions that affect their lives. Thanks to your generous donations and engagement, we: Offered a record number of health education programs. Issued groundbreaking reports. Advocated for
0 Comments
It remains “unclear” whether the modest effects of gefapixant, an investigational drug for chronic cough, represent a clinically meaningful benefit, said FDA staff ahead of a meeting of the agency’s Pulmonary-Allergy Drugs Advisory Committee. On Friday, committee members will wrestle with exactly what constitutes a meaningful benefit for this incredibly common condition, as no threshold
0 Comments
[embedded content] Internal medicine and rheumatology specialist Siobhan Deshauer, MD, takes us through a medical case study: cardiac arrest after red meat consumption. Following is a transcript of the video (note that errors are possible): Deshauer: Hey, guys. I’m Siobhan, an internal medicine and rheumatology specialist. Today, I’m going to tell you about Tom, a
0 Comments
ANAHEIM, Calif. — Peanut-allergic toddlers who stayed on an investigational, epicutaneous immunotherapy skin patch reached higher levels of peanut tolerance during the second year, according to the open-label extension of the EPITOPE trial. In children ages 1 to 3 years assigned to the patch during the randomized portion of the trial, the percentage whose bodies
0 Comments
ANAHEIM, Calif. — Adding leukotriene receptor antagonists (LTRAs) to antihistamines appears to reduce the severity of chronic urticaria, according to a systematic review and meta-analysis of randomized trials. Among 33 unique randomized trials including over 3,100 patients, high-certainty evidence suggested a mean difference in weekly Urticaria Activity Score (UAS7) of -5.17 (95% CI -6.53 to
0 Comments
ANAHEIM, Calif. — A comprehensive, smartphone app-based program failed to reduce healthcare utilization among asthma patients with private insurance, but did benefit those on Medicaid, a large randomized controlled trial found. Emergency department (ED) visits over 12 months were no different for commercially insured participants randomized to the active arm of the study (where the
0 Comments
ANAHEIM, Calif. — Treatment with remibrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, led to fast improvement in symptom control for patients with chronic spontaneous urticaria (CSU) inadequately controlled by antihistamines, results from the phase III REMIX-1 and -2 studies showed. At 12 weeks, the least-squares mean change in weekly Urticaria Activity Scores (UAS7) from
0 Comments
ANAHEIM, Calif. — ChatGPT did a fairly good job at sifting through notable allergy myths, but the AI software sometimes gave conflicting answers and allergists themselves failed to agree on how accurate its verdicts were. Researchers asked ChatGPT whether 10 supposed allergy myths were true or false, then asked 24 allergists to evaluate ChatGPT’s responses.
0 Comments
ANAHEIM, Calif. — Many primary care physicians (PCPs) remain unfamiliar with biologic therapy options for uncontrolled asthma, which impacted the rate at which they referred patients to an asthma specialist, a survey-based descriptive study showed. Of the PCPs surveyed, 42% reported that they were not familiar with biologics, while 45% said they were somewhat familiar
0 Comments
This time of year, people are going house-to-house for gatherings of friends, family, and coworkers, and it’s always thoughtful to bring the host a small gift. There are so many options out there, but some may not be ideal for those with allergies or asthma. Here are a few things to avoid and alternative ideas
0 Comments
Pre-existing asthma and rhinitis were associated with an increased risk of long-term COVID symptoms in a meta-analysis, though the link was questionable. Low-certainly evidence indicated that asthma was associated with an increased risk of developing long COVID in hospital-based populations (OR 1.94, 95% CI 1.08-3.50), reported Christian Apfelbacher, PhD, of the University of Magdeburg in
0 Comments
Oral Immunotherapy, or OIT, and Sublingual Immunotherapy (SLIT), are often talked about as treatments for food allergy. Each treatment has benefits, but they are different approaches. Let’s talk about how they differ, and how that can impact which approach to choose. The only way to treat the cause of allergies is through immunotherapy, where tiny
0 Comments
Artificial intelligence (AI) and natural language processing tools can build an algorithm that identifies patients with chronic obstructive pulmonary disease (COPD) at risk for exacerbations, according to research presented at the CHEST annual meeting hosted by the American College of Chest Physicians. In this exclusive MedPage Today video, investigator Reynold Panettieri Jr., MD, of the
0 Comments
Sexual and gender minoritized (SGM) adults are at increased risk for severe asthma, according to an analysis of a nationally representative study presented at the CHEST annual meeting hosted by the American College of Chest Physicians. In this exclusive MedPage Today video, investigator Tugba Kaplan, MD, of Luminis Health-Anne Arundel Medical Center in Annapolis, Maryland,
0 Comments
Remibrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, was safe and efficacious in patients with chronic spontaneous urticaria (CSU), a phase IIb extension study showed. In nearly 200 patients who received at least one dose of remibrutinib, complete response to treatment, measured by a weekly Urticaria Activity Score (UAS7) of zero, was observed in 28.2%
0 Comments
Welcome to our October research update! Getting involved with research is an important way to impact asthma and allergy treatments, education, and awareness. This month, we are highlighting clinical trials, interviews, focus groups, and news on: Asthma Chronic spontaneous urticaria (CSU) Epinephrine for allergic reactions Atopic dermatitis and EoE treatments New CDC data on long
0 Comments
According to the Food and Drug Administration (FDA), GlaxoSmithKline (GSK) is discontinuing production of Flovent HFA (fluticasone propionate) and Flovent Diskus. Flovent HFA and Flovent Diskus are inhaled corticosteroid medicines used as a controller medicine to treat asthma. GSK notified the FDA of this decision on June 2, 2023. The last date the product will
0 Comments
As-needed albuterol-budesonide (Airsupra) more effectively improved lung function in moderate-to-severe asthma than as-needed albuterol only, according to research presented at the CHEST annual meeting hosted by the American College of Chest Physicians. In this exclusive MedPage Today video, study author Reynold Panettieri Jr., MD, vice chancellor for Translational Medicine and science director of Rutgers Institute
0 Comments